111, Inc. Achieves Non-GAAP Profitability for Third Consecutive Quarter
- Financial Performance: 111, Inc. reported net revenues of RMB 3.0 billion (approximately $421.5 million) for Q3 2025, reflecting a 16.7% year-over-year decline, yet achieved non-GAAP operational profitability for the third consecutive quarter amidst macroeconomic challenges.
- Strategic Shift: The company divested 100% equity interests in three self-operated subsidiaries, which may temporarily impact revenue but strengthens liquidity and profitability by transitioning to an asset-light model, enhancing long-term financial health.
- Supply Chain Optimization: Through the ongoing 'MANTIANXING' initiative, the fulfillment center network has expanded, generating RMB 498 million in inventory value, driving 20.5% GMV growth and 31.0% increase in customer count, significantly enhancing overall competitiveness.
- Future Outlook: 111, Inc. aims to build an AI-powered pharmaceutical procurement transaction platform, leveraging AI to optimize decision-making and enhance customer experience, which is expected to unlock long-term value for shareholders.
Trade with 70% Backtested Accuracy
Analyst Views on YI
About YI
About the author
111, Inc. Achieves Non-GAAP Profitability for Third Consecutive Quarter
- Financial Performance: 111, Inc. reported net revenues of RMB 3.0 billion (approximately $421.5 million) for Q3 2025, reflecting a 16.7% year-over-year decline, yet achieved non-GAAP operational profitability for the third consecutive quarter amidst macroeconomic challenges.
- Strategic Shift: The company divested 100% equity interests in three self-operated subsidiaries, which may temporarily impact revenue but strengthens liquidity and profitability by transitioning to an asset-light model, enhancing long-term financial health.
- Supply Chain Optimization: Through the ongoing 'MANTIANXING' initiative, the fulfillment center network has expanded, generating RMB 498 million in inventory value, driving 20.5% GMV growth and 31.0% increase in customer count, significantly enhancing overall competitiveness.
- Future Outlook: 111, Inc. aims to build an AI-powered pharmaceutical procurement transaction platform, leveraging AI to optimize decision-making and enhance customer experience, which is expected to unlock long-term value for shareholders.
111, Inc. Transitions to Asset-Light Model, Achieves Non-GAAP Profitability for Three Consecutive Quarters
- Financial Performance: 111, Inc. reported third-quarter net revenues of RMB 3.0 billion (approximately $421.5 million), a 16.7% year-over-year decline, yet achieved non-GAAP net income of RMB 1.1 million (about $0.2 million), demonstrating resilience in profitability amidst market challenges.
- Cost Control: Operating expenses decreased to RMB 180.3 million (approximately $25.3 million), down 13.4% from the previous year, reflecting effective structural optimization and a shift to an asset-light model that enhances liquidity and profitability.
- Strategic Transition: The company divested three self-operated subsidiaries, moving towards an asset-light partnership network, which is expected to improve operational efficiency and reduce capital burdens, thereby supporting future high-margin growth.
- Supply Chain Optimization: The
111, Inc. Announces Second Quarter 2025 Unaudited Financial Results
Financial Performance: 111, Inc. reported a net revenue of RMB 3.2 billion for Q2 2025, a 6.4% decrease year-over-year, while maintaining operational profitability and positive cash flow, with operating expenses reduced by 9.3% compared to the previous year.
Strategic Initiatives: The company is focusing on enhancing its supply chain capabilities and digital marketing efforts, achieving a 53.6% increase in sales revenue from marketing promotional products and expanding fulfillment centers to 19 locations nationwide.
111, Inc. Announces First Quarter 2025 Unaudited Financial Results
Financial Performance: 111, Inc. reported stable net revenues of RMB 3.5 billion for Q1 2025, with a slight year-over-year decrease in income from operations and a net loss of RMB 7.3 million, while maintaining positive operating cash flow and reducing operating expenses as a percentage of revenues.
Operational Efficiency: The company achieved a 4.8% reduction in total operating expenses compared to the previous year, highlighting improvements in operational efficiency driven by cost management strategies, particularly in selling, marketing, and technology expenses.
111 Q1 Loss Widens, Net Revenues Flat
Financial Performance: 111, Inc. reported a wider net loss of RMB17.65 million in Q1 due to increased expenses, with nearly flat net revenues of RMB3.529 billion, reflecting only a 0.02% increase from the previous year.
Future Strategy: CEO Junling Liu emphasized the company's focus on leveraging technology and investing in AI and digital solutions to enhance their healthcare supply chain and customer engagement.
111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results
Financial Performance: 111, Inc. reported its first-ever annual operating profit of RMB2.1 million in 2024, alongside a positive operating cash flow of RMB263 million, despite facing a challenging macroeconomic environment that led to a decrease in net revenues and gross segment profit year-over-year.
Operational Efficiency: The company improved its operational efficiency significantly, with total operating expenses as a percentage of revenues decreasing by 230 basis points to 5.7% for the fiscal year, while also achieving notable reductions in various expense categories, including selling and marketing costs.
111, Inc. Achieves Non-GAAP Profitability for Third Consecutive Quarter
- Financial Performance: 111, Inc. reported net revenues of RMB 3.0 billion (approximately $421.5 million) for Q3 2025, reflecting a 16.7% year-over-year decline, yet achieved non-GAAP operational profitability for the third consecutive quarter amidst macroeconomic challenges.
- Strategic Shift: The company divested 100% equity interests in three self-operated subsidiaries, which may temporarily impact revenue but strengthens liquidity and profitability by transitioning to an asset-light model, enhancing long-term financial health.
- Supply Chain Optimization: Through the ongoing 'MANTIANXING' initiative, the fulfillment center network has expanded, generating RMB 498 million in inventory value, driving 20.5% GMV growth and 31.0% increase in customer count, significantly enhancing overall competitiveness.
- Future Outlook: 111, Inc. aims to build an AI-powered pharmaceutical procurement transaction platform, leveraging AI to optimize decision-making and enhance customer experience, which is expected to unlock long-term value for shareholders.
111, Inc. Transitions to Asset-Light Model, Achieves Non-GAAP Profitability for Three Consecutive Quarters
- Financial Performance: 111, Inc. reported third-quarter net revenues of RMB 3.0 billion (approximately $421.5 million), a 16.7% year-over-year decline, yet achieved non-GAAP net income of RMB 1.1 million (about $0.2 million), demonstrating resilience in profitability amidst market challenges.
- Cost Control: Operating expenses decreased to RMB 180.3 million (approximately $25.3 million), down 13.4% from the previous year, reflecting effective structural optimization and a shift to an asset-light model that enhances liquidity and profitability.
- Strategic Transition: The company divested three self-operated subsidiaries, moving towards an asset-light partnership network, which is expected to improve operational efficiency and reduce capital burdens, thereby supporting future high-margin growth.
- Supply Chain Optimization: The
111, Inc. Announces Second Quarter 2025 Unaudited Financial Results
Financial Performance: 111, Inc. reported a net revenue of RMB 3.2 billion for Q2 2025, a 6.4% decrease year-over-year, while maintaining operational profitability and positive cash flow, with operating expenses reduced by 9.3% compared to the previous year.
Strategic Initiatives: The company is focusing on enhancing its supply chain capabilities and digital marketing efforts, achieving a 53.6% increase in sales revenue from marketing promotional products and expanding fulfillment centers to 19 locations nationwide.
111, Inc. Announces First Quarter 2025 Unaudited Financial Results
Financial Performance: 111, Inc. reported stable net revenues of RMB 3.5 billion for Q1 2025, with a slight year-over-year decrease in income from operations and a net loss of RMB 7.3 million, while maintaining positive operating cash flow and reducing operating expenses as a percentage of revenues.
Operational Efficiency: The company achieved a 4.8% reduction in total operating expenses compared to the previous year, highlighting improvements in operational efficiency driven by cost management strategies, particularly in selling, marketing, and technology expenses.
111 Q1 Loss Widens, Net Revenues Flat
Financial Performance: 111, Inc. reported a wider net loss of RMB17.65 million in Q1 due to increased expenses, with nearly flat net revenues of RMB3.529 billion, reflecting only a 0.02% increase from the previous year.
Future Strategy: CEO Junling Liu emphasized the company's focus on leveraging technology and investing in AI and digital solutions to enhance their healthcare supply chain and customer engagement.
111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results
Financial Performance: 111, Inc. reported its first-ever annual operating profit of RMB2.1 million in 2024, alongside a positive operating cash flow of RMB263 million, despite facing a challenging macroeconomic environment that led to a decrease in net revenues and gross segment profit year-over-year.
Operational Efficiency: The company improved its operational efficiency significantly, with total operating expenses as a percentage of revenues decreasing by 230 basis points to 5.7% for the fiscal year, while also achieving notable reductions in various expense categories, including selling and marketing costs.
